The unique design of the novel anti-PD-L1 antibody envafolimab fusing a single Fab domain to an ADCC/complement-dependent cytotoxicity (CDC)-silent Fc domain can improve tumor penetration and subcutaneous injectability.286 Probody technique-based anti-PD-L1 pacmilimab is proteolytically conditionally activated in tumor tissue, and may thus reduce off-target toxicity. This evidence concerns the gene CD274 and neoplasm.